14-45167133-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_020937.4(FANCM):c.1972C>T(p.Arg658*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000893 in 1,611,790 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_020937.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FANCM | NM_020937.4 | c.1972C>T | p.Arg658* | stop_gained | 11/23 | ENST00000267430.10 | NP_065988.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FANCM | ENST00000267430.10 | c.1972C>T | p.Arg658* | stop_gained | 11/23 | 1 | NM_020937.4 | ENSP00000267430.5 |
Frequencies
GnomAD3 genomes AF: 0.0000921 AC: 14AN: 152082Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000757 AC: 19AN: 251098Hom.: 0 AF XY: 0.0000589 AC XY: 8AN XY: 135722
GnomAD4 exome AF: 0.0000891 AC: 130AN: 1459590Hom.: 0 Cov.: 29 AF XY: 0.0000867 AC XY: 63AN XY: 726310
GnomAD4 genome AF: 0.0000920 AC: 14AN: 152200Hom.: 0 Cov.: 32 AF XY: 0.0000672 AC XY: 5AN XY: 74400
ClinVar
Submissions by phenotype
not provided Pathogenic:3
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Oct 04, 2023 | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Observed as apparently homozygous or as compound heterozygous with a second FANCM truncating variant in individuals with early-onset breast cancer, childhood ALL, non-obstructive azoospermia, or premature ovarian failure (PMID: 28837162, 31942822, 34568721, 34976027); Published functional studies demonstrate a damaging effect: impairment of DNA repair activity and chromosome stability, and absent protein expression (PMID: 31700994); Observed in individuals with polycythemia, breast cancer, or ovarian cancer (PMID: 21681190, 26822949, 28033443, 29351780, 31223512, 30613976, 33099839, 28837162); This variant is associated with the following publications: (PMID: 28033443, 29351780, 21681190, 28881617, 29287190, 30676620, 26822949, 32054657, 30613976, 33099839, 31223512, 28837162, 32427313, 34584094, 33471991, 35441217, 26689913, 34976027, 34568721, 31942822, 33804961, 34308104, 31700994, 32191290) - |
Likely pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jul 01, 2024 | FANCM: PVS1:Strong, PS4:Moderate - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden | Nov 03, 2021 | - - |
Fanconi anemia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 27, 2023 | This sequence change creates a premature translational stop signal (p.Arg658*) in the FANCM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FANCM are known to be pathogenic (PMID: 29895858, 30075111). This variant is present in population databases (rs368728266, gnomAD 0.02%). This variant has been observed to be homozygous in an individual with breast cancer and other oncological malignancies and in an individual with breast cancer, pancytopenia, and chromosome fragility (PMID: 28837162). In addition, this variant has been observed to be heterozygous in individuals affected with ovarian cancer, polycythemia vera, and breast cancer (PMID: 21681190, 26822949, 29351780, 29287190, 28033443, 28881617); and in a large case-control study, this variant was observed more frequently in individuals with ER-negative breast cancer (OR=2.44, 95% CI [1.12-5.34], p=0.034) or triple-negative breast cancer (OR=3.79, 95% CI [1.56-9.18], p=0.009) than among controls (PMID: 31700994). ClinVar contains an entry for this variant (Variation ID: 444327). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental data suggest that this variant might not result in nonsense-mediated mRNA decay. However, experimental studies showed that it affects FANCM function (PMID: 31700994). This variant disrupts the C-terminal ERCC4 nuclease domain and the helix-hairpin-helix (HhH) motifs of the FANCM protein, which are critical for the interaction between FANCM and FAAP24, chromatin localization of the FANCM/FAAP24 complex and the activation of the FA core complex (PMID: 17289582, 23932590, 18174376, 19379763, 24003026). While functional studies have not been performed to directly test the effect of this variant on FANCM protein function, this suggests that disruption of this region of the protein may be causative of disease. For these reasons, this variant has been classified as Pathogenic. - |
FANCM-related disorder Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 13, 2024 | The FANCM c.1972C>T variant is predicted to result in premature protein termination (p.Arg658*). This variant has been reported in individuals who have developed various types of cancer, including breast, blood, and testicular cancers (AlDubayan et al. 2019. PubMed ID: 30676620; Harutyunyan et al. 2011. PubMed ID: 21681190; Lu et al. 2015. PubMed ID: 26689913; Nguyen-Dumont et al. 2018. PubMed ID: 29351780). This variant is reported in 0.016% of alleles in individuals of European (Non-Finnish) descent in gnomAD and has conflicting interpretations regarding its pathogenicity in ClinVar, ranging from uncertain to likely pathogenic to pathogenic (https://www.ncbi.nlm.nih.gov/clinvar/variation/444327/). Given the evidence, we interpret this variant as likely pathogenic. - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | curation | Sema4, Sema4 | Aug 25, 2021 | - - |
Spermatogenic failure 28 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | - | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at